ERNA
Ernexa Therapeutics Inc.Company with tickers: ERNA, ERNAW
CIK
748592
CUSIP
114082308
Shares Outstanding
1,166,333
13F Activity (30d)
18 filings
18 filers
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $5,590,000 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| Research & Development | — | ||||
| Operating Income | $-5,590,000 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| Net Income | $-5,506,000 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| EPS (Basic) | $-6.95 | USD/shares | 2026-03-31 | 10-Q | 2026-05-11 |
| EPS (Diluted) | $-6.95 | USD/shares | 2026-03-31 | 10-Q | 2026-05-11 |